CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes

Diabetologia

Volumn 58, Issue 6, 2015, Pages 1167-1174

  Buckingham, Bruce ^a,b,c,d,e,f   Cheng, Peiyao ^a,b,c,d,e,f   Beck, Roy W ^a,b,c,d,e,f   Kollman, Craig ^a,b,c,d,e,f   Ruedy, Katrina J ^a,b,c,d,e,f   Weinzimer, Stuart A ^a,b,c,d,e,f   Slover, Robert ^a,b,c,d,e,f   Bremer, Andrew A ^a,b,c,d,e,f   Fuqua, John ^a,b,c,d,e,f   Tamborlane, William ^a,b,c,d,e,f  

^a DirecNet) and Type 1 Diabetes TrialNet Study Groups   (United States)

^b DirecNet) and Type 1 Diabetes TrialNet Study Groups   (United States)

^c DirecNet) and Type 1 Diabetes TrialNet Study Groups   (United States)

^d DirecNet) and Type 1 Diabetes TrialNet Study Groups   (United States)

^e DirecNet) and Type 1 Diabetes TrialNet Study Groups   (United States)

^f DirecNet) and Type 1 Diabetes TrialNet Study Groups   (United States)

Author keywords

Clinical diabetes; Clinical science; Devices

Indexed keywords

C PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADOLESCENT; ADULT; ANALYSIS; BLOOD; BLOOD GLUCOSE MONITORING; CHILD; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; MIDDLE AGED; REFERENCE VALUES; YOUNG ADULT;

EID: 84939985506     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3559-y     Document Type: Article

References (19)

1. Sochett EB, Daneman D, Clarson C, Ehrlich RM (1987) Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetiologia 30:453–459
2. Couper JJ, Hudson I, Werther GA, Warne GL, Court JM, Harrison LC (1991) Factors predicting residual β-cell function in the first year after diagnosis of childhood type 1 diabetes. Diabetes Res Clin Pract 11:9–16
3. The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523
4. Mortensen HB, Hougaard P, Swift P et al (2009) New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32:1384–1390
5. Buckingham B, Beck RW, Ruedy KJ et al (2013) Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes. Diabetes Care 36:4030–4035
6. Diabetes Research in Children Network Study Group, Type 1 Diabetes TrialNet Study Groups (2013) The effects of inpatient closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther 15:1–8
7. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF (2006) Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 55:3344–3350
8. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31:934–939
9. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966–1971
10. Palmer J, Fleming G, Greenbaum C et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Diabetes 53:250–264, Erratum: Diabetes 2004; 53:1934
11. 2-score greater than 3). J Clin Endocrinol Metab 97:E2078–E2083
12. Ryan EA, Paty BW, Senior PA, Lakey JRT, Bigam D, Shapiro AMJ (2005) β-Score: an assessment of β-cell function after islet transplantation. Diabetes Care 28:343–347
13. Steffes MW, Sibley S, Jackson M, Thomas W (2003) β-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832–836
14. 1c levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function. Diabetes Care 35:817–820
15. Calhoun P, Lum J, Beck R, Kollman C (2013) Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes. Diabetes Technol Ther 15:758–761
16. Ward WK, Engle JM, Branigan D, El Youssef J, Massoud RG, Castle JR (2012) The effect of rising vs. falling glucose level on amperometric glucose sensor lag and accuracy in type 1 diabetes. Diabet Med 29:1067–1073
17. Castle JR, Ward WK (2010) Amperometric glucose sensors: sources of error and potential benefit of redundancy. J Diabetes Sci Technol 4:221–225
18. Diabetes Research in Children Network (DirecNet) Study Group (2006) Evaluation of factors affecting CGMS calibration. Diabetes Technol Ther 8:318–325
19. Helton KL, Ratner BD, Wisniewski NA (2011) Biomechanics of the sensor-tissue interface—effects of motion, pressure, and design on sensor performance and foreign body response—part II: examples and application. J Diabetes Sci Technol 5:647–656